Tevogen Bio Holdings Inc. Common Stock
TVGNTevogen Bio Holdings Inc. (TVGN) is a biopharmaceutical company focused on developing innovative therapies, including vaccines and treatments for infectious diseases. The company aims to leverage scientific advancements to address unmet medical needs through its research and development efforts.
Company News
Tevogen Bio was recognized by NJBIZ for its innovative ExacTcellâ„¢ platform and AI technology, with projected near-term commercial potential of $1 billion in first-year revenue and a five-year forecast of $18-22 billion.
Tevogen Bio explains its accumulated deficit of $129 million, highlighting that the majority represents non-cash expenses and is offset by additional paid-in capital, with total cash loss under $42 million.
Tevogen Bio is developing an investigational precision T cell therapy (TVGN 489) for COVID-19 and Long COVID, with a favorable safety profile demonstrated in clinical trials and plans to collaborate with government and healthcare organizations.
Tevogen expressed gratitude to HHS for addressing Long COVID, highlighting its investigational drug TVGN 489 as a potential treatment for the approximately 20 million Americans affected by the condition.
Tevogen's CEO, Dr. Ryan Saadi, donated 10,000 personal shares to the Warren Township Honorary Policemen's Benevolent Association (P.B.A.) Local 235, supporting local community and law enforcement initiatives.
